The history behind the discovery, research, and treatment of hemophilia is as complex and intriguing as the disease itself. A ...

Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

Hemophilia A is a genetic disease marked by a deficiency or ... the efficacy of Hemlibra in reducing bleeding episodes in ...

A gene transfer approach to treating the bleeding disorder hemophilia B remains safe and effective long-term, as scientists from St. Jude Children's Research Hospital and University College London ...

Discover how hemophilia A affects blood clotting, its genetic patterns, warning signs, advanced treatment options, and lifestyle modifications ...

APRIL marks National Hemophilia Awareness Month in the Philippines. Hemophilia is a medical condition often unseen, yet it is a deeply challenging internal battle for those who live with it.

Hemophilia significantly impacts lives beyond bleeding episodes, causing absenteeism, pain, and disability. India, with the second-highest hemophilia ...

Hemophilia is a rare disorder in which the blood doesn't clot properly because it doesn't have enough blood-clotting proteins ...

“Hemophilia can be a lifelong condition, but with the right awareness, early diagnosis, and proper treatment, people can lead normal and fulfilling lives.

World Hemophilia Day 2025 highlights global awareness and calls for inclusive care for everyone affected by bleeding disorders.

Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.

For the seventh time in the last three years, the FDA has approved a hemophilia drug, signing off on Sanofi’s fitusiran.